Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO).
Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30 for the first quarter of 2010. Adjusted net income decreased 2 percent to $1,258 million in the first quarter of 2011 compared to $1,282 million in the first quarter of 2010.
Abbott Reports 17.4 Percent Sales Growth
- Details
- Category: Abbott
Abbott (NYSE: ABT) announced financial results for the first quarter ended March 31, 2011. Worldwide sales increased 17.4 percent to more than $9 billion, including a favorable 1.3 percent effect of foreign exchange, which was driven by double-digit growth in each of Abbott's three major business categories.
Novartis makes strong start for the year
- Details
- Category: Novartis
Novartis' net sales rose 16% (+14% cc) to USD 14.0 billion. Currency benefited sales by 2% as the dollar weakened against most currencies. Excluding A(H1N1) pandemic flu vaccine sales and Alcon, net sales grew 10% (+8% cc).
GSK welcomes key agreement to support global preparedness against pandemic influenza
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global preparedness for a future influenza pandemic.
Roche Group's first-quarter 2011 sales on track for full-year targets
- Details
- Category: Roche
In the first three months of 2011 Group sales remained stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs.
Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550)
- Details
- Category: Pfizer
Pfizer Inc. announced top-line results from the ORAL Scan Phase 3 study (A3921044) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor.
More Pharma News ...
- Bayer's Rivaroxaban Submitted for Approval in Japan
- Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease
- Forest Laboratories Completes Acquisition of Clinical Data, Inc.
- Nycomed acquires distribution rights to product portfolio in Turkey
- Novartis discontinues clinical trial of Tasigna®
- Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled
- Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease